Webcast Alert: Aethlon Medical, Inc. Presentation at Informed Investors Biotechnology/Healthcare Virtual Stocks Forum to be Webc
July 23 2004 - 9:25AM
PR Newswire (US)
Webcast Alert: Aethlon Medical, Inc. Presentation at Informed
Investors Biotechnology/Healthcare Virtual Stocks Forum to be
Webcast on Tuesday, July 27, 2004, 10:00 am ET LA JOLLA, Calif.,
July 23 /PRNewswire/ -- Aethlon Medical, Inc. (OTC:AEMD.OB)
(BULLETIN BOARD: AEMD.OB) will present at the following forum:
What: Aethlon Medical, Inc. (OTC:AEMD.OB) (BULLETIN BOARD: AEMD.OB)
will give a presentation at Informed Investors Biotechnology
/Healthcare Virtual Stocks Forum When: July 27, 2004 @ 10:00 AM
Eastern Time Where:
http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85119 How:
Live over the Internet -- Simply log on to the web at the address
above. Contact: James Joyce, Chief Executive Officer, If you are
unable to attend the live event, the forum will be available via
webcast at
http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85119.
Aethlon Medical is pioneering the development of viral filtration
devices that rapidly reduce the presence of infectious disease and
toxins in the body. Aethlon has published compelling human blood
studies of the Hemopurifier(TM) to treat HIV/AIDS and Hepatitis-C
(HCV), and most recently, has announced that it is developing
pathogen filtration devices to treat infectious agents used in
biological warfare and terrorism. The Hemopurifier is a proprietary
platform technology that converges the established scientific
principles of affinity chromatography and hemodialysis as a means
to augment the immune response of clearing viruses and toxins from
the blood before cell and organ infection can occur. On March 4,
2004, Aethlon announced a cooperative agreement with the National
Center for Biodefense (NCBD) at George Mason University. Under the
agreement, Aethlon and the NCBD will collaborate to develop
pathogen and toxin filtration devices designed to protect the lives
of U.S. Military personnel exposed to infectious agents as a result
of biological warfare. For additional information, visit the
company's Web site at http://www.aethlonmedical.com/. FORUM
CONTACT: Cary Loeser, Informed Investors, 804-327-3407, Web site:
http://www.informedinvestors.com DATASOURCE: Aethlon Medical, Inc.
CONTACT: James Joyce, Chief Executive Officer of Aethlon Medical,
Inc., ; or Cary Loeser, Informed Investors, +1-804-327-3407, Web
site: http://www.aethlonmedical.com/
http://www.informedinvestors.com/
http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85119
Copyright